Efficacy and Safety of Immune Monotherapy or Immune-Based Combination Therapy Compared with Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma: A Meta-Analysis

1. Abstract
With the application and promotion of Immune Checkpoint Inhibitors (ICIs) in advanced hepatocellular carcinoma (HCC), their efficacy and safety are uneven. The purpose of the study is to compare the efficacy and safety of immune monotherapy or immune-based combination therapy compared with sorafenib in the first-line treatment of advanced HCC.